Medicine and Dentistry
Diabetes
100%
Maturity Onset Diabetes of the Young
87%
Impaired Glucose Tolerance
55%
Vitamin D
53%
Cardiovascular Disease
46%
Placebo
32%
Hemoglobin A1c
26%
Clinical Trial
25%
Supplementation
23%
Glycemic Control
19%
Cardiovascular System
19%
Nephropathy
18%
Glycemic
16%
Cardiovascular Risk
15%
Primary Health Care
14%
Hypoglycemia
14%
Insulin Sensitivity
13%
Canagliflozin
13%
Randomized Clinical Trial
12%
Insulin Resistance
12%
Nonalcoholic Fatty Liver
11%
Effectiveness Study
11%
Semaglutide
11%
Diabetes Prevention
11%
Adipose Tissue
11%
Glycosylated Albumin
11%
Dulaglutide
11%
Fructosamine
10%
Clinician
10%
Body Mass Index
9%
Prevalence
9%
Patient with Type 2 Diabetes
8%
Hyperhomocysteinemia
8%
Cell Function
8%
Homocysteine
8%
Oral Glucose Tolerance Test
8%
Obesity
7%
Hazard Ratio
7%
Cardiovascular Effect
7%
Apoplexy
7%
Metabolic Syndrome
7%
Medicare
7%
Insulin Release
7%
C-Peptide
7%
Liraglutide
7%
Colecalciferol
7%
Neointimal Hyperplasia
6%
Diabetic Nephropathy
6%
Behavior Therapy
6%
Kidney Function
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
97%
Cardiovascular Disease
44%
Vitamin D
34%
Placebo
32%
Inflammation
30%
Impaired Glucose Tolerance
24%
Semaglutide
23%
Hemoglobin A1c
22%
Insulin Resistance
18%
Cardiovascular Risk
18%
Mouse
17%
Pioglitazone
16%
Thiazolidinedione
15%
Disease
15%
Hypoglycemia
14%
Clinical Trial
14%
Glucagon Like Peptide 1 Receptor Agonist
14%
Liraglutide
13%
Metformin
13%
Canagliflozin
13%
Kidney Disease
12%
Fructosamine
11%
Copper Zinc Superoxide Dismutase
11%
Nonalcoholic Fatty Liver
11%
Homocysteine
11%
Glycosylated Albumin
11%
Salsalate
11%
Zucker Rat
11%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Antidiabetic Agent
9%
Glucagon-Like Peptide-1
7%
Metabolic Syndrome X
7%
C Peptide
7%
Prevalence
7%
Peroxisome Proliferator Activated Receptor Gamma Agonist
7%
Metabolic Disorder
6%
Diabetic Nephropathy
6%
Dulaglutide
6%
Dipeptidyl Peptidase IV Inhibitor
6%
Randomized Clinical Trial
6%
Randomized Controlled Trial
6%
Fatty Liver
6%
Methylphenidate
5%
Bardoxolone Methyl
5%
Palmitic Acid
5%
S-Adenosyl Methionine
5%
Acute Coronary Syndrome
5%
Effectiveness Study
5%
Minoxidil
5%
Paricalcitol
5%
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
31%
Diabetes
22%
Glycemic Control
18%
Cardiovascular Disease
13%
Insulin Resistance
13%
PPARγ Agonist
13%
Pioglitazone
12%
Vitamin D
11%
Type 2 Diabetes Prevention
11%
Homocysteine Metabolism
11%
Thiazolidinediones
9%
Insulin Resistance Syndrome
8%
Insulin
8%
Placebo
7%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
7%
Insulin Sensitizers
7%
Pre-diabetes (pre-DM)
7%
Canagliflozin
7%
Metformin
7%
Insulin-resistant Rats
6%
Hemoglobin A1c (HbA1c)
6%
Combination Therapy
6%
Cardiometabolic Effects
5%
Bardoxolone Methyl
5%
Vibration Perception Threshold
5%
Homocysteine
5%
Cell Function
5%
Baseline Data
5%
Inpatient Hypoglycemia
5%
Working Memory
5%
Long-term Safety
5%
Backseat Driver
5%
N-3 Fatty Acids
5%
Low-calorie Diet
5%
Comparative Effectiveness Studies
5%
Dual Therapy
5%
Paricalcitol
5%
Endothelial Inflammation
5%
Insulin-like
5%
Hypertension
5%
Glycemic Outcomes
5%
Diabetes Management
5%
Sildenafil
5%
Hemoglobin Glycation Index
5%
Insulin Sensitivity
5%
Quantile Regression Model
5%
Suboptimal Glycemic Control
5%
Inflammation Disorders
5%
Adipose Tissue Inflammation
5%
Clinical Analysis
5%